US/UK/Canada

Share

About Us

Phase Holographic Imaging (PHI) develops and markets instrumentation for non-invasive time-lapse imaging. The company’s HoloMonitor product line is used for long-term quantitative analysis of living cell cultures, particularly in preclinical research and regenerative medicine. PHI is based in Lund, Sweden and Boston, Massachusetts.

Contacts

  • Anders Månsson

    CEO


    Skiffervägen 48, 224 78, Lund
    http://www.phiab.com

    • Links

    Pick a time period -
    Tags ( Active)

    PHI announces outcome of rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The subscription period in Phase Holographic Imaging PHI AB’s ("PHI" or the "Company") rights issue of shares

    Founder and board member subscribes for shares in the ongoing rights issue

    Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB (“PHI” or the “Company”) has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.Peter Egelberg, founding Board Member of PHI, comments “The lack of robust automation has long limited the use of microscopy in manufacturing environments. Since resigning as CEO, I have gone back to my roots in software development, AI, physics and mathematics to

    PHI at Aktieportföljen Live, BioStock and Financial Stockholm

    The subscription period in Phase Holographic Imaging PHI AB’s ("PHI" or the "Company") fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans at BioStock, Aktieportföljen Live and Financial Stockholm. Månsson has also been interviewed by the podcast Fill or Kill, to give more insight to the Company and its market potential. For links to the presentations and the podcast, see below.Investor presentations and podcast BioStock 3 December 2024

    Notice of General Meeting in Phase Holographic Imaging PHI AB (publ)

    The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the general meeting must: · be entered into the share register maintained by Euroclear Sweden AB on 23 December 2024; · notify their participation to the Company no later than 30 December 2024. Notification of participation can be made by e-mail to ir@phiab.se. Notification can

    The subscription period in PHI’s fully secured rights issue commences today

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. Today, 6 December 2024, the subscription period in Phase Holographic Imaging PHI AB’s ("PHI" or the "Company")

    PHI publishes prospectus due to upcoming rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. Phase Holographic Imaging PHI AB ("PHI" or the "Company") has prepared an EU Growth Prospectus (the "Prospectus"

    New CEO of PHI to BioStock: “We show increasing sales but there is still a lot of untapped potential”

    PHI specializes in non-invasive cell analysis, enabling researchers to study cells without disrupting their natural state. The company’s products and technology are utilized by customers worldwide. Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.Watch the full video interview with Anders Månsson and Goran Dubravčić at biostock.se. https://www.biostock.se/en/2024/12/we-show-increasing-sales-but-there-is-still-a-lot-of-untapped-potential-says-new-

    Bulletin from Extraordinary General Meeting of Phase Holographic Imaging PHI AB (publ)

    Today, 2 December 2024, an Extraordinary General Meeting was held in Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”). The adopted resolution is summarized below. The resolution was adopted with the required majority. For more detailed information about the content of the resolution, please see the notice to the Meeting and the complete resolution, which have previously been published and are available on the Company's website, www.phiab.com.Approval of the board's resolution on a rights issue The Extraordinary General Meeting resolved to approve the board's

    Altium SA places order to a value of EUR 460 K and PHI communicates sales outlook

    Phase Holographic Imaging PHI AB ("PHI" or the "Company") today announces that the Company’s global distributor Altium SA (“Altium”) has placed an order of HoloMonitor® systems and add-ons to a total value of approximately EUR 460 K. The total expected order value from Altium for the full fiscal year of 2024/2025 is estimated to amount to approximately EUR 2 million.Order from Altium The order placed by Altium, amounting to a total value of approximately EUR 460 K, is expected to be shipped in December 2024, meaning that this is assessed to be recognized in the Company’s Q3-report for

    Early publication of Interim Report 2, 2024/2025

    Phase Holographic Imaging PHI AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for Q2, 2024/2025 to November 28, 2024.Phase Holographic Imaging PHI AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for Q2, 2024/2025 to November 28, 2024. This is because the company wishes to publish the report prior to the Extraordinary General Meeting planned for Dec 2.

    Notice of Extraordinary General Meeting in Phase Holographic Imaging PHI AB (publ) 2 December 2024

    Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the general meeting must: · be recorded as shareholder in the share register prepared by Euroclear Sweden AB regarding the conditions on the record date of 22 November 2024, and · notify the Company no later than 26 November 2024. Notification can be made in writing to Phase Holographic Imaging PHI AB,

    PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Phase Holographic Imaging PHI AB ("PHI" or the "Company") has today resolved on a

    Adopting the final Annual Report

    PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.It has come to the attention of Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company") that the annual report for the fiscal year 2023/2024 that was made available and presented at the annual general meeting held on 31 October 2024 was not the final and audited version. Furthermore, Leland Foster has declined to be reelected to the board. The correct and audited annual report for the fiscal

    PHI's new CEO to BioStock: "I am excited to lead us forward with new energy"

    Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. We spoke with him about his vision for the future.Read the full interview with Anders Månsson at biostock.se: https://www.biostock.se/en/2024/11/phis-new-ceo-i-am-excited-to-lead-us-forward-with-new-energy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

    Phase Holographic Imaging PHI AB (publ), reg.no 556542-7811 (the “Company”) held its annual general meeting on 31 October 2024. The following resolutions were made.Adoption of the income statement and balance sheet The annual general meeting resolved to adopt the board of directors’ proposal for the income statement and the balance sheet for the fiscal year of 2023/24. Disposition of the Company’s profit or loss The annual general meeting resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid and that the result for the year is carried forward.

    PHI secures a loan from Altium SA

    Phase Holographic Imaging PHI AB ("PHI") announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.Altium SA has provided PHI with a loan of SEK 7 million, granting PHI funds to repay a previous loan raised from Bizcap AB earlier this year. The loan has an interest rate of 1.5 percent per month, and a maturity date on the 30[th] of June 2025. PHI can repay the loan and interest at any time before the maturity date. The Board of Directors of PHI and Altium SA, as

    PHI AB’s warrant exercise registered at the Swedish Companies Registration Office

    Phase Holographic Imaging PHI AB ("PHI" or "Company") today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with PHI’s rights issue of units in 2022, ended. As a result of the warrant exercise, 1,129,513 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 4 amounts to 27,322,438 and

    PHI appoints Anders Månsson as new CEO

    The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson."I and the board are very pleased to welcome Anders as the new CEO of PHI. His solid background and experience in the life science industry is a strong asset to us. I would also like to extend a warm thank you to Patrik for his time as CEO. Under Patrik’s leadership, the company has expanded its market share and deepened collaborations

    Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise

    On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s ("PHI" or the “Company") rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.Outcome of the exercise of warrants of series TO 4 During the exercise period, 12 september-3 October 2024, holders of TO 4 had the right to subscribe for

    BioStock: PHI accelerates growth with record order

    Phase Holographic Imaging recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.Read the full interview with Patrik Eschricht at biostock.se: https://www.biostock.se/en/2024/10/phi-accelerates-growth-with-record-order/ This is a press release

    Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

    The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the annual general meeting must: · be entered into the share register maintained by Euroclear Sweden AB on 23 October 2024. · give notice to the company no later than 25 October 2024. Notification of participation can be made by e-mail to ir@phiab.se. Notification can also be made

    The last day of trading in warrants of series TO 4 is on 1 October 2024

    The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB's ("PHI" or the "Company") preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.In connection with the Company's preferential rights issue of units carried out in the Spring of 2022, 1,346,162 warrants of series TO 4 were issued. Holders of TO 4 have the right to subscribe for one (1) new share in PHI at a price of SEK 4.63 per share during the exercise period, which runs until 3 October

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media